Medicilon
美迪西
Executive Summary
Medicilon is a Shanghai-based preclinical CRO providing drug discovery, DMPK, and safety assessment services to global biotech clients through its main operating subsidiary. The company faces significant BIOSECURE Act risk due to congressional pressure and its mainland China operations serving US pharma clients. As a service provider rather than asset developer, Medicilon offers limited pipeline value but represents the CRO sector's vulnerability to US-China decoupling in pharmaceutical services.
Structure: Medicilon appears to operate through a direct subsidiary structure with Shanghai Medicilon Inc. as the primary operating entity in mainland China. The listed parent company (688202.SS) likely maintains direct ownership of the operating CRO business without complex VIE arrangements typical of internet companies.
Latest Financials
Revenue: 801725512.27, Net Profit: -128675088.23. Source: East Money (688202)
Period: 2024-09-30 | Source: eastmoney
Ownership & Shareholder Structure
Tigermed → Medicilon
Both Chinese CROs competing for multinational pharma clinical trial contracts.
Subsidiaries & Affiliates(1)
| Entity | Type | Jurisdiction | Scope | Flags | BIOSECURE |
|---|---|---|---|---|---|
Shanghai Medicilon Inc. 上海美迪西生物医药股份有限公司 | operating | mainland china | Preclinical CRO. Drug discovery, DMPK, safety assessment for global biotech clients. | CDMO | DIRECT |
Corporate Events
美迪西：美迪西：2025年度业绩快报公告
CNINFO announcement for Medicilon (688202.SS)
美迪西：美迪西：2025年年度业绩预告
CNINFO announcement for Medicilon (688202.SS)
美迪西：美迪西：股东减持股份计划公告
CNINFO announcement for Medicilon (688202.SS)
美迪西：美迪西：股东提前终止减持计划暨减持股份结果公告
CNINFO announcement for Medicilon (688202.SS)
美迪西：广发证券股份有限公司关于上海美迪西生物医药股份有限公司2025年度持续督导现场检查报告
CNINFO announcement for Medicilon (688202.SS)
Medicilon Financial Report
Revenue: 801725512.27, Net Profit: -128675088.23. Source: East Money (688202)
BIOSECURE Risk
Company faces congressional pressure regarding BIOSECURE Act compliance and operates core CRO services from mainland China, creating direct exposure for US pharma clients
Key Exposures:
- •Congressional pressure on BIOSECURE compliance
- •Core preclinical CRO operations in mainland China
- •Direct service relationships with US biotech clients
Mitigation: No public mitigation efforts identified in available data
BD Intelligence
Therapeutic Areas:
Recent Deals: No recent out-licensing deals recorded - company operates as service provider
Approach: US BD teams should exercise extreme caution given BIOSECURE risks; consider alternative CRO providers in friendlier jurisdictions
Red Flags
- ⚠Congressional pressure regarding BIOSECURE Act compliance
- ⚠Potential service disruption risk for existing US clients
- ⚠Regulatory uncertainty affecting long-term client relationships
- ⚠No visible BIOSECURE mitigation strategy
Quick Facts
- Key People
- 0
- Subsidiaries
- 1
- CDMO/CRO Subs
- 1
- Genomics Subs
- 0
- Direct BIOSECURE
- 1
- Corp Events
- 6
- Gov-Connected
- 0
- Clinical Trials
- 0
- Publications
- 0
- Drug Molecules
- 0
- Relationships
- 3
Sources & Methodology
Clinical trials data: ClinicalTrials.gov API v2 (0 trials linked to this entity)
SEC BIOSECURE filings: EDGAR EFTS full-text search (850+ filings from 230 companies)
Publications: Europe PMC API (0 publications indexed)
Drug molecules: ChEMBL database (European Bioinformatics Institute)
Financial data: East Money (东方财富) datacenter API / CNINFO (巨潮资讯网)
Corporate structure: HKEX annual reports, HKEX Disclosure of Interests
Executive profiles: Company official biographies, SEC filings, LinkedIn (where verified)
Data is collected from public sources and updated weekly. Corporate intelligence is verified by a native Mandarin-speaking analyst against Chinese-language primary sources including Tianyancha (天眼查), GSXT (国家企业信用信息公示系统), and CNINFO (巨潮资讯网). This is not financial or legal advice.